US · RPRX
Royalty Pharma plc
- Sector
- Healthcare · Biotechnology
- Headquarters
- New York City, NY 10022
- Website
- royaltypharma.com
Price · as of 2025-12-31
$49.47
Market cap 19.8B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $84.97 | +71.76% |
| Intrinsic Value(DCF) | $30.15 | -39.05% |
| Graham-Dodd Method(GD) | $8.64 | -82.53% |
| Graham Formula(GF) | $23.05 | -53.4% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | $0.00 | $77.77 | |||
| 2019 | $19.08 | $60.26 | |||
| 2020 | $41.74 | $52.44 | $7.70 | $9.60 | $61.27 |
| 2021 | $34.64 | $45.31 | $33.36 | $11.08 | $23.29 |
| 2022 | $30.53 | $33.88 | $5.89 | $1.92 | $0.59 |
| 2023 | $28.79 | $73.64 | $20.04 | $15.25 | $33.22 |
| 2024 | $32.24 | $77.09 | $10.91 | $12.54 | $8.66 |
| 2025 | $47.47 | $84.97 | $17.47 | $8.64 | $23.05 |
AI valuation
Our deep-learning model estimates Royalty Pharma plc's (RPRX) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $84.97
- Current price
- $49.47
- AI upside
- +71.76%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$30.15
-39.05% upside
Graham-Dodd
$8.64
-82.53% upside
Graham Formula
$23.05
-53.4% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| RPRX | Royalty Pharma plc | $49.47 | 19.8B | +72% | -39% | -83% | -53% | 15.48 | 3.17 | 8.62 | 17.62 | 64.14 | 3.69 | 100.00% | 65.58% | 32.42% | 19.73% | 11.31% | 7.00% | 1.38 | 5.07 | 0.97 | 2.39 | 5.09 | 2414.00% | 506.00% | -1008.00% | 12.14% | 3.91 | 18.06% | 1.84% | 28.60% | 7.83% | 18.48 | 11.57 | 12.12 | 1.79 |
| EXEL | Exelixis, Inc. | $44.06 | 11.81B | +59% | -51% | -50% | -3% | 14.24 | 5.16 | 4.80 | 11.13 | 24.57 | 5.31 | 96.39% | 37.59% | 33.73% | 35.53% | 55.80% | 27.02% | 0.08 | — | 3.56 | 3.32 | -0.34 | 5795.00% | 698.00% | 3322.00% | 7.58% | 2.18 | 64.97% | 0.00% | 0.00% | 11.04% | 11.76 | 12.15 | 4.42 | 12.01 |
| FMS | Fresenius Medical Care AG… | $23.46 | 13.52B | -1% | -60% | +12% | -19% | 11.94 | 0.82 | 0.60 | 7.06 | 14.46 | -21.51 | 25.62% | 9.31% | 4.98% | 6.78% | 6.03% | 3.03% | 0.76 | — | 1.26 | 0.76 | 3.11 | 8261.00% | 151.00% | 54.00% | 14.52% | 0.41 | 7.11% | 3.47% | 41.50% | 13.67% | 11.43 | 12.31 | 1.06 | 1.31 |
| GMAB | Genmab A/S | $29.44 | 18.14B | +21% | -15% | -44% | -6% | 19.14 | 3.16 | 4.95 | 16.85 | — | -5.09 | 91.69% | 33.60% | 25.89% | 16.63% | 16.30% | 9.62% | 0.95 | 20.49 | 2.02 | 2.01 | 2.90 | -1936.00% | 1023.00% | -336.00% | 6.23% | 0.83 | 18.73% | 0.00% | 0.00% | 2.33% | 17.81 | 19.37 | 5.98 | 2.77 |
| HOLX | Hologic, Inc. | $75.36 | 16.82B | +9% | -53% | -75% | -67% | 30.11 | 3.37 | 4.15 | 17.05 | — | 20.82 | 61.00% | 17.42% | 13.80% | 11.12% | 10.86% | 6.23% | 0.52 | 16.73 | 3.75 | 2.87 | 0.65 | -2500.00% | 174.00% | -1964.00% | 5.40% | 1.08 | 16.84% | 0.00% | 0.00% | 4.42% | 24.44 | 18.97 | 4.26 | 4.18 |
| INCY | Incyte Corporation | $101.27 | 20.15B | +47% | +302% | -42% | +85% | 15.18 | 3.78 | 3.80 | 9.10 | 0.36 | 3.97 | 91.47% | 26.12% | 25.03% | 29.87% | 69.44% | 20.75% | 0.01 | 553.03 | 3.32 | 3.04 | -1.72 | 417333.00% | 2122.00% | 44387.00% | 6.94% | 0.93 | 90.63% | 0.00% | 0.00% | 7.19% | 11.93 | 11.82 | 3.12 | 8.52 |
| ROIV | Roivant Sciences Ltd. | $28.94 | 20.71B | +3% | -75% | -82% | -98% | -22.84 | 1.74 | 280.39 | -3.06 | — | 1.74 | 96.86% | -3453.32% | -591.96% | -6.70% | 1167.58% | -5.64% | 0.02 | — | 33.47 | 32.71 | 2.38 | -10459.00% | -1119.00% | 1010.00% | -10.36% | -5.62 | 982.26% | 0.00% | 0.00% | 15.88% | -3.35 | -3.98 | 115.63 | 20.07 |
| SMMT | Summit Therapeutics Inc. | $16.59 | 12.35B | — | — | — | — | -11.21 | 18.37 | — | -14.24 | -3.08 | 18.43 | 0.00% | — | — | -206.10% | 2928.71% | -181.94% | 0.02 | — | 9.87 | 9.77 | 0.26 | 36452.00% | — | 12749.00% | -2.67% | -4.42 | 1166.77% | 0.00% | 0.00% | 0.93% | -14.04 | -35.25 | — | 72.96 |
| SNN | Smith & Nephew plc | $36.90 | 16.13B | +1% | -68% | — | -68% | 30.99 | 2.43 | 2.20 | 12.51 | — | 10.58 | 69.64% | 11.31% | 7.09% | 7.86% | 6.81% | 4.05% | 0.63 | 3.91 | 2.89 | 1.19 | 2.18 | -2167.00% | 470.00% | 23481.00% | 4.75% | 0.64 | 7.59% | 2.56% | 79.40% | 3.19% | 23.55 | 25.53 | 2.66 | 3.29 |
| THC | Tenet Healthcare Corporat… | $239.39 | 21.04B | -32% | -53% | -100% | -28% | 15.18 | 5.06 | 1.00 | 7.36 | — | -2.57 | 41.41% | 16.46% | 6.60% | 33.54% | 19.78% | 4.80% | 3.12 | — | 1.76 | 1.22 | 2.39 | -5263.00% | 312.00% | 12670.00% | 11.85% | 0.79 | 16.87% | 0.00% | 0.00% | 11.50% | 9.02 | 12.51 | 1.48 | 2.07 |
| UTHR | United Therapeutics Corpo… | $503.90 | 22.79B | -28% | -44% | -38% | +9% | 17.05 | 3.21 | 7.15 | 11.66 | 130.50 | 3.26 | 87.92% | 46.89% | 41.94% | 19.71% | 25.78% | 17.51% | 0.00 | 76.54 | 6.60 | 3.40 | -0.86 | 1307.00% | 1061.00% | -369.00% | 4.57% | 2.78 | 23.09% | 0.00% | 0.00% | 5.10% | 14.21 | 20.38 | 6.66 | 20.45 |
About Royalty Pharma plc
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
- CEO
- Pablo Legorreta
- Employees
- 75
- Beta
- 0.42
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($30.15 ÷ $49.47) − 1 = -39.05% (DCF, example).